Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
04:05pm, Wednesday, 19'th Feb 2025
Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $74
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
10:30am, Monday, 17'th Feb 2025
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
BioMarin to Report Q4 Earnings: Here's What to Expect
08:21am, Monday, 17'th Feb 2025
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics
10:16am, Thursday, 13'th Feb 2025
Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 12'th Feb 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Wednesday, 12'th Feb 2025
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Growth Investors Will Love BioMarin (BMRN)
01:45pm, Wednesday, 05'th Feb 2025
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
SAN RAFAEL, Calif. , Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe
4 Stocks That Sport Impressive Interest Coverage Ratio
10:11am, Tuesday, 04'th Feb 2025
BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 27'th Jan 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents i
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
10:45am, Monday, 27'th Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
10:42am, Thursday, 23'rd Jan 2025
BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's da
These 4 Stocks Boast Impressive Interest Coverage Ratio
11:20am, Wednesday, 22'nd Jan 2025
BMRN, AMZN, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Here is Why Growth Investors Should Buy BioMarin (BMRN) Now
01:46pm, Monday, 20'th Jan 2025
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
11:06am, Tuesday, 14'th Jan 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p
